M Alfa-Wali1, T Allen-Mersh1, A Antoniou2, D Tait3, T Newsom-Davis4, B Gazzard4, M Nelson4, M Bower5. 1. Department of Surgery and Cancer, Imperial College London, London. 2. Department of Surgery and Cancer, Imperial College London, London; Department of Surgery, Institute of Cancer Research, London. 3. Department of Clinical Oncology, Royal Marsden Hospital. 4. Departments of Oncology; HIV Medicine, Chelsea and Westminster Hospital, London, UK. 5. Department of Surgery and Cancer, Imperial College London, London; Departments of Oncology; HIV Medicine, Chelsea and Westminster Hospital, London, UK. Electronic address: m.bower@imperial.ac.uk.
Abstract
BACKGROUND: Despite the advent of highly active antiretroviral therapy, anal cancer remains a significant health problem in human immunodeficiency virus (HIV) patients. We present the clinical features and treatment outcomes of anal cancer in 60 HIV-positive patients over a 20-year period. PATIENTS AND METHODS: A prospective database of all HIV-positive individuals managed in a specialist unit since 1986 includes 11 112 patients (71 687 person-years of follow-up). Sixty patients with anal cancer were identified. Their clinicopathological and treatment details were analysed. RESULTS: At anal cancer diagnosis, the mean age was 44 years (range: 28-75 years) and the median CD4 cell count was 305 mm(-3) (range: 16-1252 mm(-3)). Fifty (83%) had chemoradiotherapy (CRT). Forty-six (92%) responded, of whom 10 (22%) subsequently relapsed with locoregional (70%), metastatic disease (10%) or both (20%). The overall 5-year survival is 65% (95% confidence interval 51% to 78%). The median CD4 count fell from 289 mm(-3) before CRT to 132 mm(-3) after 3 months and to 189 mm(-3) after 1 year (P<0.05). Six patients in remission of anal cancer died of acquired immunodeficiency syndrome defining illnesses. CONCLUSIONS: The management of anal cancer with CRT achieves similar outcomes as the general population. CRT is associated with significant prolonged CD4 suppression that may contribute to late deaths of patients in remission.
BACKGROUND: Despite the advent of highly active antiretroviral therapy, anal cancer remains a significant health problem in human immunodeficiency virus (HIV) patients. We present the clinical features and treatment outcomes of anal cancer in 60 HIV-positivepatients over a 20-year period. PATIENTS AND METHODS: A prospective database of all HIV-positive individuals managed in a specialist unit since 1986 includes 11 112 patients (71 687 person-years of follow-up). Sixty patients with anal cancer were identified. Their clinicopathological and treatment details were analysed. RESULTS: At anal cancer diagnosis, the mean age was 44 years (range: 28-75 years) and the median CD4 cell count was 305 mm(-3) (range: 16-1252 mm(-3)). Fifty (83%) had chemoradiotherapy (CRT). Forty-six (92%) responded, of whom 10 (22%) subsequently relapsed with locoregional (70%), metastatic disease (10%) or both (20%). The overall 5-year survival is 65% (95% confidence interval 51% to 78%). The median CD4 count fell from 289 mm(-3) before CRT to 132 mm(-3) after 3 months and to 189 mm(-3) after 1 year (P<0.05). Six patients in remission of anal cancer died of acquired immunodeficiency syndrome defining illnesses. CONCLUSIONS: The management of anal cancer with CRT achieves similar outcomes as the general population. CRT is associated with significant prolonged CD4 suppression that may contribute to late deaths of patients in remission.
Authors: Francesco R Simonetti; Michele D Sobolewski; Elizabeth Fyne; Wei Shao; Jonathan Spindler; Junko Hattori; Elizabeth M Anderson; Sarah A Watters; Shawn Hill; Xiaolin Wu; David Wells; Li Su; Brian T Luke; Elias K Halvas; Guillaume Besson; Kerri J Penrose; Zhiming Yang; Richard W Kwan; Carter Van Waes; Thomas Uldrick; Deborah E Citrin; Joseph Kovacs; Michael A Polis; Catherine A Rehm; Robert Gorelick; Michael Piatak; Brandon F Keele; Mary F Kearney; John M Coffin; Stephen H Hughes; John W Mellors; Frank Maldarelli Journal: Proc Natl Acad Sci U S A Date: 2016-02-08 Impact factor: 11.205
Authors: Deborah Citrin; Luca Valle; Kevin Camphausen; Theresa Cooley-Zgela; Deedee Smart; Michael Yao; James B Mitchell; William Thompson; Irini Sereti; Thomas Uldrick Journal: Int J Oncol Date: 2022-04-19 Impact factor: 5.650
Authors: Jessica P Hwang; Bruno P Granwehr; Harrys A Torres; Maria E Suarez-Almazor; Thomas P Giordano; Andrea G Barbo; Heather Y Lin; Michael J Fisch; Elizabeth Y Chiao Journal: J Oncol Pract Date: 2015-08-04 Impact factor: 3.840
Authors: Marcos Pedro Guedes Camandaroba; Raphael Leonardo Cunha de Araujo; Virgílio Souza E Silva; Celso Abdon Lopes de Mello; Rachel P Riechelmann Journal: J Gastrointest Oncol Date: 2019-02
Authors: Keri L Calkins; Geetanjali Chander; Corinne E Joshu; Kala Visvanathan; Anthony T Fojo; Catherine R Lesko; Richard D Moore; Bryan Lau Journal: JAMA Oncol Date: 2020-02-01 Impact factor: 31.777
Authors: Daria Gotti; Elena Raffetti; Laura Albini; Laura Sighinolfi; Franco Maggiolo; Elisa Di Filippo; Nicoletta Ladisa; Gioacchino Angarano; Giuseppe Lapadula; Angelo Pan; Anna Degli Esposti; Massimiliano Fabbiani; Emanuele Focà; Alfredo Scalzini; Francesco Donato; Eugenia Quiros-Roldan Journal: PLoS One Date: 2014-04-23 Impact factor: 3.240
Authors: Ira L Leeds; Hasan Alturki; Joseph K Canner; Eric B Schneider; Jonathan E Efron; Elizabeth C Wick; Susan L Gearhart; Bashar Safar; Sandy H Fang Journal: World J Surg Oncol Date: 2016-08-05 Impact factor: 2.754